Express Scripts to cover AbbVie's new Hepatitis C treatment but not Gilead's Sovaldi

Express Scripts, one of the largest pharmacy benefit managers in the country, will cover AbbVie's new hepatitis C treatment and will no longer cover Gilead Sciences treatments, according to a Reuters report.

Express Scripts has opposed the price of Gilead Sciences' Sovaldi treatment — $84,000 — since it was approved. The pharmacy benefits manager said that it was unaffordable. AbbVie's Viekira Pak drug, recently approved by the U.S. Food and Drug Administration, has a significantly lower price, Express Scripts CMO Steve Miller.

More articles on gastroenterology:

Adopting the updated GI procedure quality metrics & what this means for practice
Making the most of 2015: New Year’s resolutions in GI
10 most-read GI/endoscopy stories of 2014

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like

 

Featured Whitepapers

Featured Webinars